FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2057290717> ?p ?o ?g. }

• W2057290717 endingPage "746" @default.
• W2057290717 startingPage "746" @default.
• W2057290717 abstract "Background: Dose-intensive intravenous melphalan with autologous blood stem-cell transplantation induces remission of the plasma cell dyscrasia in a substantial proportion of patients with AL amyloidosis. The impact of this treatment on associated renal disease is not known. Objective: To determine the effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on AL amyloidosis–associated renal disease. Design: Prospective cohort study. Setting: Academic medical center. Patients: 65 patients with AL amyloidosis and urinary protein excretion greater than 1 g/24 h who received dose-intensive intravenous melphalan and autologous blood stem-cell transplantation between 1 July 1994 and 30 June 1998. Measurements: 24-hour urinary protein excretion, serum cholesterol level, serum albumin level, creatinine clearance, urine and serum immunoelectrophoresis, and bone marrow biopsy. Renal response was defined as a greater than 50% reduction in urinary protein excretion in the absence of a 25% or greater reduction in creatinine clearance. Complete hematologic response was defined as absence of detectable monoclonal protein in serum and urine and a bone marrow specimen containing less than 5% plasma cells without clonal dominance of κ or λ isotype. Results: Among the 50 patients who survived for at least 12 months, proteinuria, hypoalbuminemia, and hypercholesterolemia improved during follow-up; 36% met criteria for a renal response. Median 24-hour urinary protein excretion decreased from a baseline value of 9.6 g/24 h to 1.6 g/24 h at 12 months among patients with complete hematologic response, and 71% met criteria for a renal response. Twenty-hour urinary protein excretion did not decrease during follow-up among patients with persistent plasma cell disease, and only 11% had a renal response at 12 months (P < 0.001 for hematologic responders vs. nonresponders). Conclusion: Dose-intensive intravenous melphalan with autologous blood stem-cell transplantation improves the nephrotic syndrome in patients with AL amyloidosis–associated renal disease. The benefit is largely limited to patients achieving eradication of the underlying plasma cell dyscrasia." @default.
• W2057290717 created "2016-06-24" @default.
• W2057290717 creator A5026644077 @default.
• W2057290717 creator A5027206522 @default.
• W2057290717 creator A5033811813 @default.
• W2057290717 creator A5045583989 @default.
• W2057290717 creator A5051039977 @default.
• W2057290717 creator A5051085359 @default.
• W2057290717 creator A5062036170 @default.
• W2057290717 creator A5071439155 @default.
• W2057290717 date "2001-05-01" @default.
• W2057290717 modified "2023-09-26" @default.
• W2057290717 title "Effect of Dose-Intensive Intravenous Melphalan and Autologous Blood Stem-Cell Transplantation on AL Amyloidosis–Associated Renal Disease" @default.
• W2057290717 cites W146910030 @default.
• W2057290717 cites W156595675 @default.
• W2057290717 cites W1968002068 @default.
• W2057290717 cites W1970184528 @default.
• W2057290717 cites W1973601639 @default.
• W2057290717 cites W1978475423 @default.
• W2057290717 cites W2034053702 @default.
• W2057290717 cites W2069078219 @default.
• W2057290717 cites W2075391935 @default.
• W2057290717 cites W2089163478 @default.
• W2057290717 cites W2102506290 @default.
• W2057290717 cites W2106283558 @default.
• W2057290717 cites W2120793724 @default.
• W2057290717 cites W2319723388 @default.
• W2057290717 cites W2332241363 @default.
• W2057290717 cites W2340841673 @default.
• W2057290717 cites W39461475 @default.
• W2057290717 cites W86094332 @default.
• W2057290717 cites W2420771240 @default.
• W2057290717 doi "https://doi.org/10.7326/0003-4819-134-9_part_1-200105010-00011" @default.
• W2057290717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11329232" @default.
• W2057290717 hasPublicationYear "2001" @default.
• W2057290717 type Work @default.
• W2057290717 sameAs 2057290717 @default.
• W2057290717 citedByCount "118" @default.
• W2057290717 countsByYear W20572907172012 @default.
• W2057290717 countsByYear W20572907172013 @default.
• W2057290717 countsByYear W20572907172014 @default.
• W2057290717 countsByYear W20572907172015 @default.
• W2057290717 countsByYear W20572907172016 @default.
• W2057290717 countsByYear W20572907172017 @default.
• W2057290717 countsByYear W20572907172018 @default.
• W2057290717 countsByYear W20572907172019 @default.
• W2057290717 countsByYear W20572907172020 @default.
• W2057290717 countsByYear W20572907172021 @default.
• W2057290717 countsByYear W20572907172023 @default.
• W2057290717 crossrefType "journal-article" @default.
• W2057290717 hasAuthorship W2057290717A5026644077 @default.
• W2057290717 hasAuthorship W2057290717A5027206522 @default.
• W2057290717 hasAuthorship W2057290717A5033811813 @default.
• W2057290717 hasAuthorship W2057290717A5045583989 @default.
• W2057290717 hasAuthorship W2057290717A5051039977 @default.
• W2057290717 hasAuthorship W2057290717A5051085359 @default.
• W2057290717 hasAuthorship W2057290717A5062036170 @default.
• W2057290717 hasAuthorship W2057290717A5071439155 @default.
• W2057290717 hasConcept C126322002 @default.
• W2057290717 hasConcept C126894567 @default.
• W2057290717 hasConcept C159654299 @default.
• W2057290717 hasConcept C203014093 @default.
• W2057290717 hasConcept C2778684742 @default.
• W2057290717 hasConcept C2779050716 @default.
• W2057290717 hasConcept C2779551797 @default.
• W2057290717 hasConcept C2780306776 @default.
• W2057290717 hasConcept C2780411336 @default.
• W2057290717 hasConcept C2911091166 @default.
• W2057290717 hasConcept C36394416 @default.
• W2057290717 hasConcept C71924100 @default.
• W2057290717 hasConcept C90924648 @default.
• W2057290717 hasConceptScore W2057290717C126322002 @default.
• W2057290717 hasConceptScore W2057290717C126894567 @default.
• W2057290717 hasConceptScore W2057290717C159654299 @default.
• W2057290717 hasConceptScore W2057290717C203014093 @default.
• W2057290717 hasConceptScore W2057290717C2778684742 @default.
• W2057290717 hasConceptScore W2057290717C2779050716 @default.
• W2057290717 hasConceptScore W2057290717C2779551797 @default.
• W2057290717 hasConceptScore W2057290717C2780306776 @default.
• W2057290717 hasConceptScore W2057290717C2780411336 @default.
• W2057290717 hasConceptScore W2057290717C2911091166 @default.
• W2057290717 hasConceptScore W2057290717C36394416 @default.
• W2057290717 hasConceptScore W2057290717C71924100 @default.
• W2057290717 hasConceptScore W2057290717C90924648 @default.
• W2057290717 hasIssue "9_Part_1" @default.
• W2057290717 hasLocation W20572907171 @default.
• W2057290717 hasLocation W20572907172 @default.
• W2057290717 hasOpenAccess W2057290717 @default.
• W2057290717 hasPrimaryLocation W20572907171 @default.
• W2057290717 hasRelatedWork W1980048113 @default.
• W2057290717 hasRelatedWork W1999107549 @default.
• W2057290717 hasRelatedWork W2012879531 @default.
• W2057290717 hasRelatedWork W2039532382 @default.
• W2057290717 hasRelatedWork W2081068834 @default.
• W2057290717 hasRelatedWork W2083725549 @default.
• W2057290717 hasRelatedWork W2497923819 @default.
• W2057290717 hasRelatedWork W2558690251 @default.
• W2057290717 hasRelatedWork W2992485704 @default.

• next